Product image of Navidoxine (Meclozine Hydrochloride) supplied by GNH India

Navidoxine

Active Ingredient:
Meclozine Hydrochloride
Origin:
EU

Navidoxine (Meclozine Hydrochloride)

Meclozine Hydrochloride, the active ingredient in Navidoxine, is an H1‑receptor antagonist presented as an oral dosage form for oral use. It is employed to alleviate symptoms of motion‑induced nausea, vertigo, and other vestibular‑related disturbances in adults and adolescents. By blocking peripheral histamine receptors and providing modest anticholinergic activity, it reduces vestibular stimulation that contributes to nausea and dizziness.

GNH India supplies Navidoxine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gen.Orph

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Navidoxine, an H1‑receptor antagonist, is used in disorders where vestibular histamine activity contributes to symptoms.

  • Motion sickness: reduces nausea, vomiting and dizziness caused by travel or movement.
  • Vertigo: alleviates spinning sensations associated with vestibular dysfunction.
  • Vestibular‑related nausea: diminishes nausea linked to inner‑ear disorders.

How It Works

  • Meclozine Hydrochloride acts as a competitive antagonist at peripheral histamine H1 receptors, preventing histamine‑mediated excitation of the vestibular apparatus. Its additional anticholinergic activity dampens vestibular nerve firing, thereby decreasing the central perception of motion and reducing associated nausea and vertigo.

Side Effects

Navidoxine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Drowsiness: feeling unusually sleepy or fatigued.
  • Dry mouth: reduced salivation leading to a parched sensation.
  • Blurred vision: temporary difficulty focusing.
  • Constipation: slowed intestinal transit.
  • Headache: mild to moderate head pain.
  • Fatigue: general lack of energy.

Serious or Rare Side Effects

  • Allergic reactions: rash, itching, swelling, or angioedema.
  • Cardiac arrhythmia: irregular heartbeats, reported rarely.
  • Severe hypotension: marked drop in blood pressure.
  • Seizures: uncommon but possible in susceptible individuals.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Extrapyramidal symptoms: rare movement disorders.

Precautions & Warnings

Before prescribing Navidoxine, clinicians should consider several safety factors.

  • Assess renal function: adjust use if severe impairment is present.
  • Evaluate hypersensitivity: avoid in patients with known allergy to meclozine or related antihistamines.
  • Caution in the elderly: increased risk of sedation and falls.
  • Limit alcohol consumption: may enhance central nervous system depression.
  • Pregnancy and lactation: use only when the potential benefit justifies the potential risk.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Navidoxine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Central nervous system depressants (e.g., benzodiazepines, opioids): may potentiate sedation and respiratory depression.
  • Other anticholinergic agents (e.g., atropine, trihexyphenidyl): additive anticholinergic effects can cause severe dry mouth, constipation, or urinary retention.
  • Alcohol: synergistic drowsiness and impaired coordination.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: possible enhancement of blood‑pressure‑lowering effects.

  • Additional antihistamines: cumulative sedation.
  • CYP450 inhibitors (e.g., erythromycin, ketoconazole): may increase meclozine plasma concentrations.
  • Diuretics: potential for electrolyte imbalance when combined with anticholinergic effects.
  • Antidepressants (e.g., tricyclics): heightened anticholinergic burden.

Frequently Asked Questions

Navidoxine is indicated for the prevention and treatment of motion‑induced nausea, vomiting and dizziness, for relief of vertigo associated with vestibular disorders, and for reducing nausea that arises from inner‑ear conditions. It is commonly prescribed to travelers, patients undergoing vestibular rehabilitation, and anyone experiencing vestibular‑related upset.

Meclozine Hydrochloride blocks peripheral H1 histamine receptors, preventing histamine‑driven excitation of the vestibular system. Its modest anticholinergic activity further dampens vestibular nerve signaling, which together reduces the brain’s perception of motion and the accompanying nausea and vertigo.

The dose of Navidoxine is individualized by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and clinical response. Health‑care professionals follow local prescribing guidelines and adjust the regimen as needed for optimal efficacy and safety.

Safety data for Meclozine Hydrochloride in pregnancy and lactation are limited. It should be used only when the potential therapeutic benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified health‑care provider.

To place an order, submit an enquiry on the Navidoxine product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both Navidoxine (meclozine) and dimenhydrinate are H1‑antihistamines used for motion‑related disorders. Navidoxine generally has a milder anticholinergic profile, which may result in less drowsiness for some patients, while dimenhydrinate often produces stronger sedation. Choice of therapy depends on individual tolerance, comorbidities and physician preference.

Navidoxine should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

Navidoxine is taken orally, usually with a glass of water. It may be administered with or without food, although taking it with a light meal can reduce occasional stomach upset. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a health‑care professional.

Serious adverse events, though rare, include severe allergic reactions such as rash, swelling or angioedema, cardiac arrhythmias, marked hypotension, and seizures. Patients should seek immediate medical attention if they experience difficulty breathing, rapid heartbeat, fainting, or any signs of an allergic response.

Navidoxine should be avoided in individuals with known hypersensitivity to meclozine or other H1‑antihistamines, in patients with severe hepatic impairment, and in those taking medications that could cause dangerous additive anticholinergic effects. Caution is also advised for patients with uncontrolled glaucoma, urinary retention, or severe constipation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Meclozine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT